The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma

被引:51
作者
Diouf, Momar [1 ,2 ,3 ]
Filleron, Thomas [4 ]
Barbare, Jean-Claude [1 ]
Fin, Loic [1 ]
Picard, Carl [1 ]
Bouche, Olivier [5 ]
Dahan, Laetitia [6 ,7 ]
Paoletti, Xavier [8 ,9 ]
Bonnetain, Franck [2 ,3 ]
机构
[1] Amiens Univ Hosp, Clin Res & Innovat Directorate, Amiens, France
[2] CHU Besancon, EA 3181, Methodol & Qual Life Oncol Unit, Dijon, France
[3] Qual Vie & Canc Clin Res Platform, Dijon, France
[4] Claudius Regaud Inst, Biostat Unit, Toulouse, France
[5] Reims Univ Hosp, Dept Hepatogastroenterol, Reims, France
[6] La Timone Univ Hosp, AP HM, Dept Hepatogastroenterol & Digest Oncol, Marseille, France
[7] Univ Mediterranean, Marseille, France
[8] Inst Curie, Biostat Serv, Paris, France
[9] INSERM, U900, Paris, France
关键词
Quality of life; Prognosis; Hepatocellular carcinoma; Palliative; Improvement; METASTATIC COLORECTAL-CANCER; CHEMOEMBOLIZATION; MULTICENTER; VALIDATION; QLQ-C30; MODEL;
D O I
10.1016/j.jhep.2012.11.019
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background 82 Aims: Several prognostic classifications (PCs) have been developed for use in palliative care in patients with hepatocellular carcinoma (HCC). We have recently suggested that CLIP combined with WHO PS has the greatest discriminative power. We evaluated the prognostic value of quality of life (QoL) data and whether the latter could improve classification of palliative HCC patients. Methods: This was a reanalysis from the CHOC trial with an evaluation of the discriminative power for overall survival (OS) of the established CLIP/GRETCH/BCLC/BoBar prognostic systems alone and then in association with each of the following groups of parameters: selected clinical factors, QoL as continuous variables, dichotomized QoL, selected clinical factors and continuous QoL, selected clinical factors and dichotomized QoL. Baseline QoL was assessed using the EORTC QLQ-C30. Discriminative power was evaluated with the Harrell's C-index and net reclassification improvement. Results: Quality of life was available in 79% of the patients (n = 271). Univariate analysis revealed that better role functioning (HR = 0.991 [0.987-0.995]) and better physical functioning (0.991 [0.984-0.9971) scores were associated with longer survival. In contrast, poorer score for fatigue (1.011 [1.006-1.015]) and diarrhoea (1.008 [1.002-1.013]) were associated with shorter survival. After adjustment for clinical and sociodemographic variables, only better role functioning score (0.993 [0.988-0.998]) was associated with longer survival. Adding oedema, hepatomegaly, fatigue and diarrhoea QoL scales to CLIP resulted in the best performance. Conclusions: Our results confirm that QoL scales are independent prognostic factors of OS in palliative HCC patients. Incorporation of QoL data improved all the studied PCs. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:509 / 521
页数:13
相关论文
共 42 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study [J].
Barbare, Jean-Claude ;
Bouche, Olivier ;
Bonnetain, Franck ;
Dahan, Laetitia ;
Lombard-Bohas, Catherine ;
Faroux, Roger ;
Raoul, Jean-Luc ;
Cattan, Stephane ;
Lemoine, Alain ;
Blanc, Jean-Frederic ;
Bronowicki, Jean-Pierre ;
Zarski, Jean-Pierre ;
Cazorla, Sophie ;
Gargot, Dany ;
Thevenot, Thierry ;
Diaz, Emmanuel ;
Bastie, Anne ;
Aparicio, Thomas ;
Bedenne, Laurent .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) :1788-1797
[3]   Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18 [J].
Blazeby, JM ;
Currie, E ;
Zee, BCY ;
Chie, WC ;
Poon, RT ;
Garden, OJ .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (16) :2439-2444
[4]   Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma:: results from two French clinical trials [J].
Bonnetain, Franck ;
Paoletti, Xavier ;
Collette, Sandra ;
Doffoel, Michel ;
Bouche, Olivia ;
Raoul, Jean Luc ;
Rougier, Philippe ;
Masskouri, Fadil ;
Barbare, Jean Claude ;
Bedenne, Laurent .
QUALITY OF LIFE RESEARCH, 2008, 17 (06) :831-843
[5]   A new prognostic classification for predicting survival in patients with hepatocellular carcinoma [J].
Chevret, S ;
Trinchet, JC ;
Mathieu, D ;
Rached, AA ;
Beaugrand, M ;
Chastang, C .
JOURNAL OF HEPATOLOGY, 1999, 31 (01) :133-141
[6]   Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study [J].
Chibaudel, Benoist ;
Bonnetain, Franck ;
Tournigand, Christophe ;
Bengrine-Lefevre, Leila ;
Teixeira, Luis ;
Artru, Pascal ;
Desrame, Jerome ;
Larsen, Annette K. ;
Andre, Thierry ;
Louvet, Christophe ;
de Gramont, Aimery .
ONCOLOGIST, 2011, 16 (09) :1228-1238
[7]   Developing a prognostic model in the presence of missing data: an ovarian cancer case study [J].
Clark, TG ;
Altman, DG .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (01) :28-37
[8]   Prognosis of advanced hepatocellular carcinoma:: comparison of three staging systems in two French clinical trials [J].
Collette, S. ;
Bonnetain, F. ;
Paoletti, X. ;
Doffoel, M. ;
Bouche, O. ;
Raoul, J. L. ;
Rougier, P. ;
Masskouri, F. ;
Bedenne, L. ;
Barbare, J. C. .
ANNALS OF ONCOLOGY, 2008, 19 (06) :1117-1126
[9]   Use and misuse of the receiver operating characteristic curve in risk prediction [J].
Cook, Nancy R. .
CIRCULATION, 2007, 115 (07) :928-935
[10]   Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (federation francophone de cancerologie digestive 9402) [J].
Doffoel, M. ;
Bonnetain, F. ;
Bouche, O. ;
Vetter, D. ;
Abergel, A. ;
Fratte, S. ;
Grange, J. D. ;
Stremsdoerfer, N. ;
Blanchi, A. ;
Bronowicki, J. P. ;
Caroli-Bosc, F. X. ;
Causse, X. ;
Masskouri, F. ;
Rougier, P. ;
Bedenne, L. .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (04) :528-538